1 active not recruiting, 1 recruiting. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Ashibio Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton. Andecaliximab - Heterotopic Ossification (HO) | Phase 1 / Phase 2 | Recruiting | Ashibio Inc | 10 | 2025-05-14 | 2025-06-17 |
| A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) Andecaliximab, Placebo - Fibrodysplasia Ossificans Progressiva | Phase 2 / Phase 3 | Active not recruiting | Ashibio Inc | 92 | 2024-10-25 | 2025-10-14 |
Ossification, Heterotopic (2) · Hallux Valgus (1) · Inflammation (1) · Muscular Diseases (1) · Musculoskeletal Diseases (1) · Myositis (1) · Myositis Ossificans (1)
andecaliximab (2)
United States (2)
Andrew Park, MD (1)